Methylprednisolone in adults hospitalized with COVID-19 pneumonia
Purpose To determine whether a 6-day course of methylprednisolone (MP) improves outcome in patients with severe SARS-CoV‑2 (Corona Virus Disease 2019 [COVID-19]). Methods The study was a multicentric open-label trial of COVID-19 patients who were aged ≥ 18 years, receiving oxygen without mechanical ventilation, and with evidence of systemic inflammatory response who were assigned to standard of care (SOC) or SOC plus intravenous MP (40 mg bid for 3 days followed by 20 mg bid for 3 days). The primary outcome was a composite of death, admission to the intensive care unit, or requirement for noninvasive ventilation. Both intention-to-treat (ITT) and per protocol (PP) analyses were performed. Results A total of 91 patients were screened, and 64 were randomized (mean age70 ± 12 years). In the ITT analysis, 14 of 29 patients (48%) in the SOC group and 14 of 35 (40%) in the MP group suffered the composite endpoint (40% versus 20% in patients under 72 years and 67% versus 48% in those over 72 years; p = 0.25). In the PP analysis, patients on MP had a significantly lower risk of experiencing the composite endpoint (age-adjusted risk ratio 0.42; 95% confidence interval, CI 0.20–0.89; p = 0.043). Conclusion The planned sample size was not achieved, and our results should therefore be interpreted with caution. The use of MP had no significant effect on the primary endpoint in ITT analysis; however, the PP analysis showed a beneficial effect due to MP, which consistent with other published trials support the use of glucocorticoids in severe cases of COVID-19..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:133 |
|---|---|
| Enthalten in: |
Wiener klinische Wochenschrift - 133(2021), 7-8 vom: 03. Feb., Seite 303-311 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Corral-Gudino, Luis [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: | |
|---|---|
| Themen: |
Coronavirus Infections |
| doi: |
10.1007/s00508-020-01805-8 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR043842860 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR043842860 | ||
| 003 | DE-627 | ||
| 005 | 20230519074240.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210424s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00508-020-01805-8 |2 doi | |
| 035 | |a (DE-627)SPR043842860 | ||
| 035 | |a (DE-599)SPRs00508-020-01805-8-e | ||
| 035 | |a (SPR)s00508-020-01805-8-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 070 |a 610 |q ASE |
| 084 | |a 44.00 |2 bkl | ||
| 084 | |a 44.60 |2 bkl | ||
| 100 | 1 | |a Corral-Gudino, Luis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Methylprednisolone in adults hospitalized with COVID-19 pneumonia |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Purpose To determine whether a 6-day course of methylprednisolone (MP) improves outcome in patients with severe SARS-CoV‑2 (Corona Virus Disease 2019 [COVID-19]). Methods The study was a multicentric open-label trial of COVID-19 patients who were aged ≥ 18 years, receiving oxygen without mechanical ventilation, and with evidence of systemic inflammatory response who were assigned to standard of care (SOC) or SOC plus intravenous MP (40 mg bid for 3 days followed by 20 mg bid for 3 days). The primary outcome was a composite of death, admission to the intensive care unit, or requirement for noninvasive ventilation. Both intention-to-treat (ITT) and per protocol (PP) analyses were performed. Results A total of 91 patients were screened, and 64 were randomized (mean age70 ± 12 years). In the ITT analysis, 14 of 29 patients (48%) in the SOC group and 14 of 35 (40%) in the MP group suffered the composite endpoint (40% versus 20% in patients under 72 years and 67% versus 48% in those over 72 years; p = 0.25). In the PP analysis, patients on MP had a significantly lower risk of experiencing the composite endpoint (age-adjusted risk ratio 0.42; 95% confidence interval, CI 0.20–0.89; p = 0.043). Conclusion The planned sample size was not achieved, and our results should therefore be interpreted with caution. The use of MP had no significant effect on the primary endpoint in ITT analysis; however, the PP analysis showed a beneficial effect due to MP, which consistent with other published trials support the use of glucocorticoids in severe cases of COVID-19. | ||
| 650 | 4 | |a Glucocorticoids |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a SARS-CoV-2 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Mortality |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Coronavirus Infections |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Humans |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Bahamonde, Alberto |e verfasserin |4 aut | |
| 700 | 1 | |a Arnaiz-Revillas, Francisco |e verfasserin |4 aut | |
| 700 | 1 | |a Gómez-Barquero, Julia |e verfasserin |4 aut | |
| 700 | 1 | |a Abadía-Otero, Jesica |e verfasserin |4 aut | |
| 700 | 1 | |a García-Ibarbia, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Mora, Víctor |e verfasserin |4 aut | |
| 700 | 1 | |a Cerezo-Hernández, Ana |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández, José L. |e verfasserin |4 aut | |
| 700 | 1 | |a López-Muñíz, Graciela |e verfasserin |4 aut | |
| 700 | 1 | |a Hernández-Blanco, Fernando |e verfasserin |4 aut | |
| 700 | 1 | |a Cifrián, Jose M. |e verfasserin |4 aut | |
| 700 | 1 | |a Olmos, Jose M. |e verfasserin |4 aut | |
| 700 | 1 | |a Carrascosa, Miguel |e verfasserin |4 aut | |
| 700 | 1 | |a Nieto, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Fariñas, María Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Riancho, José A. |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Wiener klinische Wochenschrift |d Wien : Springer, 2003 |g 133(2021), 7-8 vom: 03. Feb., Seite 303-311 |w (DE-627)SPR006547729 |w (DE-600)2244243-1 |x 1613-7671 |7 nnns |
| 773 | 1 | 8 | |g volume:133 |g year:2021 |g number:7-8 |g day:03 |g month:02 |g pages:303-311 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s00508-020-01805-8 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |q ASE |
| 936 | b | k | |a 44.60 |q ASE |
| 951 | |a AR | ||
| 952 | |d 133 |j 2021 |e 7-8 |b 03 |c 02 |h 303-311 | ||